Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Vilarrasa, Eva
- dc.contributor.author Nicolau, Joana
- dc.contributor.author Cueva, Pablo de la
- dc.contributor.author Goday Arno, Alberto
- dc.contributor.author Gallardo Hernández, Fernando
- dc.contributor.author Martorell, Antonio
- dc.contributor.author Carrascosa Carrillo, José Manuel
- dc.date.accessioned 2024-04-24T06:48:36Z
- dc.date.available 2024-04-24T06:48:36Z
- dc.date.issued 2024
- dc.description.abstract Psoriasis and hidradenitis suppurativa are often associated with obesity. Because chronic low-grade inflammation underlies these 2 diseases, they can progress to more severe forms in patients with obesity if weight-reduction measures are not taken. This review covers pharmacologic alternatives for treating obesity, with emphasis on the benefits associated with the novel use of glucagon-like peptide-1 (GLP-1) agonists that act on satiety receptors. These drugs have led to greater weight loss in clinical trials and real-world settings than orlistat, which until recently was the only drug approved for treating obesity in the European Union. Although experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce, the promising results reported suggest they may offer a useful tool for managing obesity.
- dc.format.mimetype application/pdf
- dc.identifier.citation Vilarrasa E, Nicolau J, de la Cueva P, Goday A, Gallardo F, Martorell A, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024 Jan;115(1):T56-T65. DOI: 10.1016/j.ad.2023.10.019
- dc.identifier.doi http://dx.doi.org/10.1016/j.ad.2023.10.019
- dc.identifier.issn 0001-7310
- dc.identifier.uri http://hdl.handle.net/10230/59888
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Actas Dermosifiliogr. 2024 Jan;115(1):T56-T65
- dc.rights © 2023 AEDV. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Psoriasis
- dc.subject.keyword Hidradenitis suppurativa
- dc.subject.keyword Obesity
- dc.subject.keyword Glucagon-like peptide-1 (GLP-1) agonists
- dc.subject.keyword Liraglutide
- dc.subject.keyword Semaglutide
- dc.title Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion